Angion’s HGF Mimetic Fails Second Phase II Study, But Not Shuttered Yet
Executive Summary
Although ANG-3777, partnered with Vifor, missed its primary endpoint in cardiovascular surgery patients at risk for acute kidney injury, the companies will consider a path forward based on a renal events measure.
You may also be interested in...
Vifor Builds Its Kidney Disease Focus With $80m Angion Deal
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.
TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Aptinyx Appears To Be Moving On From Pain With Fibromyalgia Miss
Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.